Fig. 6. ADAM2 is a bona fide cancer-testis antigen associated with reduced inflammatory responses and increased cancer hallmark pathways in human LUAD.

A Pan-cancer TCGA analysis reveals increased ADAM2 mRNA expression in multiple cancers. B RNAscope analysis of ADAM2 (green) and EPCAM (yellow) expression in testis and LUAD samples. C Quantification of ADAM2 transcripts from (B) in indicated tissues (n = 5 normal lungs; n = 8 testis; n = 96 LUAD). Data were analyzed by two-sided student’s t-test and present mean ± s.e.m. D Pathway enrichment analysis of Cancer Hallmark gene sets in 510 TCGA LUAD samples. Bar plots showing the pathways that were significantly enriched for upregulated and downregulated genes in the TCGA LUAD cohort (FDR < 0.05). Pathways enriched for upregulated genes are shown in red and pathways enriched for downregulated genes are shown in blue. -log10 transformed FDR-adjusted p values are shown on the x-axis.